SOCS1 is significantly up-regulated in Nutlin-3-treated p53 wild-type B chronic lymphocytic leukemia (BCLL) samples and shows an inverse correlation with miR-155

Investigational New Drugs

Volumn 30, Issue 6, 2012, Pages 2403-2406

  Di Iasio, Maria Grazia ^a   Norcio, Alessia ^a   Melloni, Elisabetta ^a   Zauli, Giorgio ^b  

^a UNIVERSITY OF FERRARA   (Italy)

^b INSTITUTE FOR MATERNAL AND CHILD HEALTH IRCCS BURLO GAROFOLO   (Italy)

Author keywords

MiRNA 155; Nutlin 3; Primary B CLL; SOCS1

Indexed keywords

MESSENGER RNA; MICRORNA 155; NUTLIN 3; PROTEIN MDM2; PROTEIN P53; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ARTICLE; B CELL LEUKEMIA; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CORRELATION ANALYSIS; GENE MUTATION; GRANULOCYTE; HUMAN; HUMAN CELL; LEUKEMIA CELL; MONOCYTE; NATURAL KILLER CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; UPREGULATION;

CELL LINE, TUMOR; CELLS, CULTURED; DOWN-REGULATION; HUMANS; IMIDAZOLES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; LEUKOCYTES, MONONUCLEAR; MICRORNAS; PIPERAZINES; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; UP-REGULATION;

EID: 84875531373     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-011-9786-2     Document Type: Article

References (22)

1. Secchiero P, di Iasio MG, Gonelli A, Zauli G (2008) The MDM2 inhibitor Nutlins as an innovative therapeutic tool for the treatment of haematological malignancies. Curr Pharm Des 14:2100-2110
2. Secchiero P, Zerbinati C, di Iasio MG et al (2007) Synergistic cytotoxic activity of recombinant TRAIL plus the non-genotoxic activator of the p53 pathway nutlin-3 in acute myeloid leukemia cells. Curr Drug Metab 8:395-403
3. Secchiero P, Barbarotto E, Tiribelli M et al (2006) Functional integrity of the p53-mediated apoptotic pathway induced by the non-genotoxic agent nutlin-3 in B-cell chronic lymphocytic leukemia (B-CLL). Blood 107:4122-4129
4. Saddler C, Ouillette P, Kujawski L et al (2008) Comprehensive biomarker and genomic analysis identifies p53 status as the major determinant of response to MDM2 inhibitors in chronic lympho-cytic leukemia. Blood 111:1584-1593
5. di Iasio MG, Addobbati R, Radillo O, Voltan R (2011) Nutlin-3 differentially modulates miRNA34a and miRNA181 versus miR26a and miR155 in p53 proficient and p53 deficient B chronic lymphocytic leukemia (B-CLL) samples. Invest New Drugs [Epub ahead of print]
6. Lu LF, Thai TH, Calado DP et al (2009) Foxp3-dependent micro-RNA155 confers competitive fitness to regulatory T cells through targeting SOCS1. Immunity 30:80-91
7. Jiang S, Zhang HW, Lu MH et al (2010) MicroRNA-155 functions as an OncomiR in breast cancer by targeting the suppressor of cytokine signaling 1 gene. Cancer Res 70:3119-3127
8. Alexander WS (2002) Suppressors of cytokine signalling (SOCS) in the immune system. Nat Rev Immunol 2:410-416
9. Frantsve J, Schwaller J, Sternberg DW, Kutok J, Gilliland DG (2001) Socs-1 inhibits TEL-JAK2-mediated transformation of he-matopoietic cells through inhibition of JAK2 kinase activity and induction of proteasome-mediated degradation. Mol Cell Biol 21:3547-3557
10. Reddy J, Shivapurkar N, Takahashi T et al (2005) Differential methylation of genes that regulate cytokine signaling in lymphoid and hematopoietic tumors. Oncogene 24:732-736
11. Galm O, Yoshikawa H, Esteller M, Osieka R, Herman JG (2003) SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101:2784-2788
12. Chim CS, Wong KY, Loong F, Srivastava G (2004) SOCS1 and SHP1 hypermethylation in mantle cell lymphoma and follicular lymphoma: implications for epigenetic activation of the Jak/STAT pathway. Leukemia 18:356-358
13. Secchiero P, Melloni E, di Iasio MG et al (2009) Nutlin-3 upregu-lates the expression of Notch1 in both myeloid and lymphoid leukemic cells, as part of a negative feed-back anti-apoptotic mechanism. Blood 113:4300-4308
14. + cells). J Gen Virol 73:417-421
15. Campioni D, Secchiero P, Corallini F et al (2005) Evidence for a role of TNF-related apoptosis-inducing ligand (TRAIL) in the anemia of myelodysplastic syndromes. Am J Pathol 166:557-563
16. 133 phosphorylation and activation of CREB transcription factor in both Jurkat lymphoblastoid T cells and primary peripheral blood mononuclear cells. J Immunol 160:3891-3898
17. Wang M, Tan L, Dijkstra M et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13-20
18. Androulidaki A, Iliopoulos D, Arranz A et al (2009) The kinase Akt1 controls macrophage response to lipopolysaccharide by regulating microRNAs. Immunity 31:220-231
19. Jongen-Lavrencic M, Sun SM, Dijkstra MK, Valk PJ, Lowenberg B (2008) MicroRNA expression profiling in relation to the genetic heterogeneity of acute myeloid leukemia. Blood 111:5078-5085
20. Cammarata G, Augugliaro L, Salemi D et al (2010) Differential expression of specific microRNA and their targets in acute mye-loid leukemia. Am J Haematol 85:331-339
21. Wang M, Tan LP, Dijkstra MK et al (2008) miRNA analysis in B-cell chronic lymphocytic leukaemia: proliferation centres characterized by low miR-150 and high BIC/miR-155 expression. J Pathol 215:13-20
22. Marton S, Garcia MR, Robello C et al (2008) Small RNAs analysis in CLL reveals a deregulation of miRNA expression and novel miRNA candidates of putative relevance in CLL pathogenesis. Leukemia 22:330-338